The diagnostic category of amnesia associated with mild cognitive impairment (MCI) attempts to describe those people who have memory loss but relatively preserved abilities in other cognitive areas so as not to merit a diagnosis of dementia. The importance of this group of people is that they represent a population at high risk of developing dementia, especially Alzheimer's disease, and are an appropriate target for early diagnosis and intervention strategies. Accordingly, the major goal of this proposal is to determine whether sensitive behavioral tasks together with eye-tracking technology will reveal a profile of performance in MCI patients that is useful in predicting the onset of Alzheimer's Disease or other dementias. The overall plan is to test a minimum of 60 MCI patients and 60 matched normal control (NC) subjects (recruited from the Clinical Core) initially and on yearly follow-up sessions on two declarative memory tasks and one nondeclarative memory task, together with eye-tracking. We have good experience with all of the tasks and with eye-tracking, and we have successfully administered the preferential looking task together with eye-tracking in pilot work with MCI, PD, and NC subjects. A group of 30 patients with Alzheimer's Disease (AD) and a group of 30 Parkinson's Disease patients without dementia (PD) also will be tested (these groups will also be recruited from the Clinical Core). The performance of the AD and PD groups and the NC group will provide important points of comparison with the performance of the MCI patients initially and at follow-up sessions. The PD group also serves as a critical control group for the MCI and AD patients. Specifically, PD patients, like the AD patients, have neurologic damage, but unlike AD patients, the PD patients don't have dementia. An important contribution from this work would be the ability to diagnose sooner than is now possible in MCI patients oncoming cognitive decline, at a time when the nervous system is less compromised and, accordingly, more likely to benefit from therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
1P50AG025688-01
Application #
6933615
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (J4))
Project Start
2005-06-01
Project End
2010-03-31
Budget Start
2005-06-01
Budget End
2006-04-30
Support Year
1
Fiscal Year
2005
Total Cost
$117,927
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Rangaraju, Srikant; Raza, Syed Ali; Li, Noel Xiang'An et al. (2018) Differential Phagocytic Properties of CD45low Microglia and CD45high Brain Mononuclear Phagocytes-Activation and Age-Related Effects. Front Immunol 9:405
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Chalermpalanupap, Termpanit; Schroeder, Jason P; Rorabaugh, Jacki M et al. (2018) Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice. J Neurosci 38:74-92
Maezawa, Izumi; Nguyen, Hai M; Di Lucente, Jacopo et al. (2018) Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept. Brain 141:596-612
Bishof, Isaac; Dammer, Eric B; Duong, Duc M et al. (2018) RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease. J Biol Chem 293:11047-11066
Peng, Katherine Y; Pérez-González, Rocío; Alldred, Melissa J et al. (2018) Apolipoprotein E4 genotype compromises brain exosome production. Brain :
Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98
Zhang, Qi; Ma, Cheng; Gearing, Marla et al. (2018) Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer's disease. Acta Neuropathol Commun 6:19
Umoh, Mfon E; Dammer, Eric B; Dai, Jingting et al. (2018) A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med 10:48-62
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169

Showing the most recent 10 out of 444 publications